B+
Bull case
25%
Probability
Target price
$480.00
+28.6% vs current
ELV
Elevance HealthBNYSE / Health Care Equipment & Services
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
50%
Probability
Target price
$430.00
+15.2% vs current
B-
Bear case
25%
Probability
Target price
$320.00
-14.2% vs current
AI sentiment snapshot
Latest data as of 2026-07-16
Recent news sentiment (30D)
+30.0
Positive
Company
-
Unavailable
Macro
+30.0
Positive
Pulse
-
Unavailable
Sentiment proxy
+56.9
Score
AI commentary
Primary-source tone is positive on the Q2 beat and guidance raise, but the operating read-through is mixed because medical-cost trends, membership attrition, and margin compression persist. Recent headlines indicated underperformance versus competitors and concern about the Medicaid problem, but exact post-print price reaction and analyst revisions are unavailable. Social coverage is absent and the peer set is limited, so this remains a cautious post-earnings monitoring setup.
RankAlpha Sentiment Codex - 2026-07-16
Open post-earnings memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators
Impact
tentative
Confidence
-
AI events
2026-07-15eventQ2 beat and FY26 guidance raiseMedium impact
Elevance reported Q2 revenue of $49.8 billion and adjusted EPS of $7.45, said results were ahead of expectations, and raised FY26 adjusted EPS guidance to at least $27.00 and operating cash flow guidance to at least $6.0 billion [#SEC-8K-2026-07-15].
2026-07-16catalystGovernment medical-cost and membership pressureMedium impact
The benefit expense ratio rose 80 basis points year over year to 89.7%, driven by elevated medical-cost trends in government businesses. Medical membership declined by 469,000 sequentially, reflecting customer transition and anticipated ACA and Medicaid attrition [#SEC-8K-2026-07-15].
2027-12-31catalyst2027 EPS-growth path through Carelon and cost managementHigh impact
Management expressed confidence in returning to at least 12% adjusted EPS growth in 2027, supported by medical-cost management, provider connectivity, operating efficiency, and Carelon value-based solutions [#SEC-8K-2026-07-15]. Execution remains unproven against current margin and membership pressure.
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-16 • Updated nightlySource: Internal modelMethodology